Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
A phase 3 trial of Margetuximab and Trastuzumab in Breast cancer, run by MacroGenics, completed.
Overview
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer is a phase 3 interventional study registered as NCT02492711 by MacroGenics, with 624 participants recorded, started 2015-08-24 and reaching its primary completion in 2021-08-11. Interventions recorded: Margetuximab, Trastuzumab, Physician's choice of chemotherapy.. Conditions recorded: HER-2 Positive Breast Cancer, Metastatic Neoplasm.
Linked to the drug Margetuximab because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialCombination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
Shares MacroGenics, Margetuximab, Trastuzumab and the tag pipeline.
- TrialMARGetuximab Or Trastuzumab (MARGOT)
Shares Margetuximab, Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialOptimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Shares Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialChemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Shares Breast cancer (all types), Trastuzumab and the tag pipeline.
- TreatmentLorigerlimab
Shares MacroGenics and the tag pipeline.
- TrialRC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
Shares Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialCombination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
Shares Breast cancer (all types), Trastuzumab and the tag pipeline.
- TrialSix vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer
Shares Breast cancer (all types), Trastuzumab and the tag pipeline.